AI Company Ultromics Secures $55 Million in Series C Funding for Advanced AI Cardiology Solutions
Ultromics Transforms Heart Failure Diagnostics with AI-Powered Technology
Ultromics, a pioneering AI technology company, has made a significant impact on the U.S. healthcare system by introducing the first FDA-cleared and Medicare-reimbursed technology for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. These complex and hard-to-diagnose forms of heart failure are now more accurately and objectively identified, thanks to Ultromics' EchoGo platform [1][2][4].
The EchoGo platform, a revolutionary tool in cardiology, analyses standard echocardiograms and generates real-time probability scores, improving earlier and more accurate detection without the need for new hardware or disrupting clinical workflows. Ultromics has analysed over 430,000 echocardiograms, resulting in a 73.6% improvement in HFpEF detection compared to traditional risk scores [1][2][4].
Recently, Ultromics secured $55 million in a Series C funding round to expand the deployment of its technology across at-risk hospitals and echo labs in the U.S. Major U.S. health systems like the University of Chicago Medicine supported this funding round, aiming to scale adoption further and integrate AI-enhanced diagnostics as a standard part of cardiac evaluations [1][2][3][4].
Looking ahead, Ultromics plans to broaden the accessibility of their AI tools, particularly the EchoGo Score launched in 2025, which enhances HFpEF detection with AI-driven probability scoring. The company aims to address the mounting heart failure crisis, with U.S. healthcare costs related to heart failure expected to rise from over $30 billion annually to beyond $70 billion by 2030 [1][3][4].
Ultromics' platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. By reducing undiagnosed cases and associated hospitalizations, Ultromics' solution could potentially alleviate economic and clinical burdens in cardiology [1][3][4].
The Series C funding round for Ultromics was co-led by L&G, Allegis Capital, and Lightrock, with additional support from Oxford Science Enterprises and UCHICAGO Medicine's UCM Ventures. Ross Upton, PhD, is the CEO and Founder of Ultromics [2].
When paired with the latest treatment advances, Ultromics' diagnostic approach will help save lives. The Series C funding round is a testament to the massive opportunity for technology to transform cardiovascular disease detection and treatment [1][2][3][4].
References: [1] Ultromics. (n.d.). Press Release: Ultromics Secures $55 Million Series C Funding Round. Retrieved from https://www.ultromics.com/news/press-releases/ultromics-secures-55-million-series-c-funding-round [2] Ultromics. (n.d.). About Us. Retrieved from https://www.ultromics.com/about-us [3] Ultromics. (n.d.). Our Technology. Retrieved from https://www.ultromics.com/our-technology [4] Ultromics. (n.d.). Impact. Retrieved from https://www.ultromics.com/impact
- Ultromics, a leader in AI technology and pioneer in medical-conditions, has secured $55 million in venture capital to expand the use of its AI-powered cardiovascular-health diagnostic system.
- The investment in Ultromics comes from various sources, including L&G, Allegis Capital, Lightrock, Oxford Science Enterprises, and UCHICAGO Medicine's UCM Ventures.
- With the funding, Ultromics plans to make its AI technology, including the EchoGo Score, more accessible for at-risk hospitals and echo labs, aiming to alleviate the economic and clinical burdens of the growing heart failure crisis in the United States.
- By combining AI with advancements in science, finance, and technology, Ultromics' solution is expected to improve the accuracy of heart failure diagnoses and contribute to significant advancements in health-and-wellness and artificial-intelligence sectors.
